Metraipolis › archive › dc_a8df7e910365
Novel Competitive, Nonpeptidic, SARS-CoV‑2 Mpro Inhibitors with Improved Solubility — Europe PMC PMID:42157831
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42157831
- DOI
- 10.1021/acsmedchemlett.6c00041
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T17:35:53.483Z
- SHA-256 of the archived text
ce6cf63eeb5ab920859adf6423f03bcdaa8e4e6041a451d4dfd5eb53194368c4- Stable URL of this page
https://metraipolis.com/documento/dc_a8df7e910365
How to cite
Novel Competitive, Nonpeptidic, SARS-CoV‑2 Mpro Inhibitors with Improved Solubility — Europe PMC PMID:42157831 — Europe PMC (en), https://europepmc.org/article/MED/42157831 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a8df7e910365 (Metraipolis archive dc_a8df7e910365, sha256 ce6cf63eeb5ab920859adf6423f03bcdaa8e4e6041a451d4dfd5eb53194368c4)
BibTeX
@misc{dca8df7e910365,
title = {Novel Competitive, Nonpeptidic, SARS-CoV‑2 Mpro Inhibitors with Improved Solubility — Europe PMC PMID:42157831},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42157831},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a8df7e910365; sha256 ce6cf63eeb5ab920859adf6423f03bcdaa8e4e6041a451d4dfd5eb53194368c4},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42157831. Agents can read the archived copy with the MCP tool read_document.